about
Multiple Roles for B-Lymphocytes in Sjogren's SyndromeRituximab in primary Sjögren's syndrome: a ten-year journey.The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.Increased IL-21 Expression Induces Granzyme B in Peripheral CD5(+) B Cells as a Potential Counter-Regulatory Effect in Primary Sjögren's SyndromeCentral role for marginal zone B cells in an animal model of Sjogren's syndromeCD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.Biologic treatment in Sjögren's syndrome.Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases.The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation.Safety of treatments for primary Sjögren's syndrome.The microbiome-systemic diseases connection.Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.Management of primary Sjögren's syndrome: recent developments and new classification criteria.Attenuation of Follicular Helper T Cell-Dependent B Cell Hyperactivity by Abatacept Treatment in Primary Sjögren's Syndrome.Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjögren's Syndrome: Potential New Axis in Lymphoid Neogenesis.Towards inhibition of morbidity and mortality in Sjögren's syndrome: opportunities and challenges.Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients.
P2860
Q28068695-D6FEBD50-4558-490D-AD31-C8FFE909E3DBQ34432465-75C29FFB-065C-47A0-85CC-11C952B4D26FQ35105313-009CF5D8-A2ED-444D-A27A-3CE56BFC8146Q36106681-F63424BC-B96E-46C1-B8A0-84ABC480FAE1Q36538934-D0010416-D1CC-4536-99B5-AC35112D0361Q37083549-8C34076A-FBBB-469F-9522-150AD9376284Q37645910-88257712-4AF9-4B5F-B9F9-2B160E3F5E3CQ38262453-29A869BD-93AA-4D8C-BB4E-170A01397CB4Q38647276-1605A586-EB75-448F-A49C-D24EDE091BB9Q38695851-4328E55C-26D9-4837-8D79-9443163BB284Q38711144-00143FA4-0853-4B61-848D-CB3639E985BFQ38765160-BB34E964-F0FE-4053-B400-5FD015C44D2EQ38988830-B17AA110-6B76-4C44-8F28-98EE387EB797Q40117123-A3DED336-6056-4B74-8EF7-2E31B8485C60Q47700923-54CA4913-D376-4E3F-A98D-1B3C310E6376Q47822712-505040E8-812F-4929-B5A3-0E3D50552BADQ50940710-7DBAEA3A-1EF6-433D-B9E0-71C95C56FF2FQ51291271-64FDC9A2-F1ED-4F0F-999F-64ACF8A7E626Q54384919-87B451BB-C55C-44E8-9E32-C29889081161Q55125041-834895CC-64C5-4154-AB83-07276832DFA3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
B-cell hyperactivity in primary Sjögren's syndrome.
@en
type
label
B-cell hyperactivity in primary Sjögren's syndrome.
@en
prefLabel
B-cell hyperactivity in primary Sjögren's syndrome.
@en
P2093
P2860
P1476
B-cell hyperactivity in primary Sjögren's syndrome.
@en
P2093
Arjan Vissink
Erlin Haacke
Frans G M Kroese
Hendrika Bootsma
Nicolaas A Bos
Wayel H Abdulahad
P2860
P304
P356
10.1586/1744666X.2014.891439
P577
2014-02-25T00:00:00Z